1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Shanghai RAAS Blood Products Co., Ltd. Class A

Shanghai RAAS Blood Products Co., Ltd. Class A

SSZSE:002252
4.77
CNY
-0.01
(-0.21%)
28.61BMarket Cap
Oct 28Next Earn
Shanghai RAAS Blood Products Co., Ltd. Class A
SZSE:002252
(Shenzhen Stock Exchange)

Recent

price

4.77

P/E

ratio

- -

div

yld

1.24%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.14
0.16
0.19
0.28
0.32
0.41
0.48
0.39
0.37
0.51
0.44
0.63
0.98
1.21
1.23
1.12
- -
Revenue per Share
0.05
0.06
0.06
0.08
0.12
0.29
0.33
0.17
-0.31
0.12
0.21
0.19
0.28
0.27
0.33
0.24
- -
Basic EPS, GAAP
0.03
- -
0.03
-0.12
0.1
0.12
0.1
0.02
0.02
0.14
0.15
0.16
0.22
0.28
-0.13
-0.11
- -
Free Cash Flow per Basic Share
0.03
0.03
0.04
0.01
0.02
0.03
0.04
0.04
0.03
- -
0.01
0.02
0.03
0.03
0.07
0.04
0.06
Dividend per Share
0.23
0.26
0.28
0.31
1.75
2.15
2.36
2.51
2.19
2.31
3.73
3.84
4.28
4.46
4.81
4.89
4.92
Book Value per Share
0.22
0.25
0.27
0.29
0.62
1.02
1.17
1.32
1.04
1.19
2.92
3.09
3.55
3.66
3.97
3.54
3.56
Tangible Book Value per Share
3,535
3,518
3,522
1,785
4,180
4,957
4,888
4,917
4,898
5,066
6,303
6,813
6,715
6,591
6,646
6,571
6,584
Basic Weighted Avg Shares
483
567
663
496
1,320
2,013
2,326
1,928
1,804
2,585
2,762
4,288
6,567
7,964
8,176
7,348
- -
Sales/Revenue/Turnover
43.69
40.54
38.99
37.71
44.01
42.55
47.97
43.45
30.92
36.01
38.84
34.58
30.92
29.47
26.8
22.84
- -
Operating Margin (%)
13
15
15
17
60
103
112
143
150
148
153
159
185
163
207
233
- -
Depreciation Expense
185
200
225
144
511
1,442
1,613
836
-1,518
608
1,324
1,295
1,880
1,779
2,193
1,577
- -
Net Income, GAAP
16.07
15.31
15.37
15.66
15.19
15.37
15.77
17.2
- -
17.35
10.74
16.25
17.62
19.36
16.27
17.26
- -
Effective Tax Rate (%)
38.38
35.31
33.96
28.97
38.71
71.64
69.35
43.36
-84.16
23.52
47.93
30.19
28.63
22.34
26.82
21.46
- -
Profit Margin (%)
587
545
489
806
2,342
4,560
5,201
6,275
3,488
4,222
4,682
5,566
6,849
6,431
7,606
7,215
8,242
Working Capital
- -
- -
- -
357
358
360
360
- -
- -
- -
- -
4
2
1
13
2,484
2,573
LT Debt
831
927
1,019
1,102
8,624
10,712
11,730
12,480
10,900
11,491
25,130
25,904
28,813
29,650
31,941
32,456
32,414
Total Equity
22.39
21.84
21.83
11.19
9.67
14.52
14.04
6.64
- -
5.42
7.34
5.11
6.86
6.13
7.3
4.65
- -
Return on Invested Capital (%)
23.28
22.89
22.84
12.81
10.18
14.19
13.85
7.2
- -
5.42
7.26
5.09
6.9
6.09
7.12
4.72
- -
Return on Capital (%)
23.44
23.05
23.46
13.75
10.54
14.97
14.42
6.92
-13.01
5.44
7.23
5.07
6.87
6.09
7.13
4.9
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,426
1,397
970
LT Borrowings
2,473
2,547
2,563
LT Finance Leases
10
10
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6,638
6,638
6,593
Market Capitalization
42,085
38,633
28,612

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
9,951
10,403
10,602
Cash, Cash Equivalents & STI
1,401
1,882
1,556
Accounts Receivable, Net
1,842
1,906
2,043
Inventories
5,366
5,551
5,606
Total Current Liabilities
2,736
2,792
2,360
Payables & Accruals
- -
- -
- -
ST Debt
1,426
1,397
970
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.39%
5.31%
1.61%
Free Cash Flow
41.43%
-18.16%
-20.41%
Net Income, GAAP
-30.75%
6.57%
-28.1%
Sales/Revenue/Turnover
16.43%
24.45%
-10.13%
Total Cash Common Dividend
430.73%
48.82%
-41.21%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,056
2,196
2,062
1,862
8,176
2025
2,006
1,946
- -
1,257
7,348
2026
1,509
1,700
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.07
0.09
0.05
0.33
2025
0.08
0.07
- -
0.02
0.24
2026
0.05
0.05
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.03
0.03
- -
0.07
2025
- -
- -
- -
0.01
0.04
2026
0.02
0.03
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Amgen Inc. (NASDAQ:AMGN)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
Kodiak Sciences Inc (NASDAQ:KOD)
Business
Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) engages primarily in the research, development, production and sales of plasma-derived blood products in China. Founded in 1988 and headquartered at No. 2009 Wangyuan Road, Fengxian District, Shanghai, the company operates six production bases in Shanghai, Zhengzhou, Hefei, Wenzhou, Nanning and Hengyang, along with 55 plasma donation centers across 11 provinces including Guangxi, Hunan, Hainan, Shaanxi, Anhui, Guangdong, Inner Mongolia, Zhejiang, Hubei, Jiangxi and Shandong. Its core products encompass human albumin (Albumin RAAS), human immunoglobulin (pH4) for intravenous injection (γ-RAAS), human coagulation factor VIII (Human RAAS), human fibrinogen (Fibrinogen RAAS), prothrombin complex concentrate (human), freeze-dried (Prothrombin RAAS), thrombin (human) (Thrombin RAAS) and fibrin sealant (human) (Fibrin RAAS); specific immunoglobulins such as hepatitis B immunoglobulin, tetanus immunoglobulin and rabies immunoglobulin; and additional offerings including human intravenous immunoglobulin. The company extracts six key components from plasma, positioning it among China's leaders in plasma utilization rates, coagulation factor portfolios and export capabilities to regions like Southeast Asia and Latin America. Recent developments include Haier Group's 2024 acquisition of a 20% stake through Haiyingkang, integrating Shanghai RAAS into Haier's Incaier health ecosystem and establishing strategic partnerships with Grifols for bioscience and diagnostics; a 2025 acquisition of Nanyue Biopharmaceutical for at least 4.2 billion yuan to enhance supply chain and production efficiency; a March 2024 collaboration with Boehringer Ingelheim on hemophilia innovative drugs; and the advancement of SR604 injection into phase two clinical trials for hemophilia A/B and congenital factor VII deficiency. Shanghai RAAS maintains certifications as a Shanghai Foreign-Invested Advanced Technology Enterprise and High-Tech Enterprise, emphasizing quality under its "safety, quality, efficacy" policy while serving domestic healthcare markets and contributing to national strategic reserves.